Last updated on February 2018

Cognitive Trial – A Phase III Safety and Efficacy Study of ALZT-OP1 in Individuals with Evidence of Early Alzheimer’s Disease

Other Details:

Study visits: Screening, Day 1 (Baseline), Week 4, Week 12, Week 24, Week 48, and Week 72.

Compensation: Contact to Find out More


Find a site near you

Start Over

The NeuroCognitive Institute

111 Howard Blvd, Suite 204 Mt. Arlington, NJ USA
  Connect »

Bradenton Research Center

909 Hyde Street Suite 322 Bradenton, FL USA
  Connect »

Renew Behavioral Health, Inc.

909 Hyde Street Suite 322 Long Beach, CA USA
  Connect »